Abstract: Novel compounds useful as dopamine receptor agonists for the treatment of various diseases of the central nervous system such as Parkinson's disease and related disorders having the structural formula ##STR1## where R.sub.2, R.sub.3 and R.sub.4 are each selected from the group consisting of H, and OA; A is selected from the group consisting of hydrocarbyl radicals; ##STR2## where X is S or O: and pharmaceutically acceptable salts thereof. Also disclosed is a method for inducing a dopaminergic response in a patient by adminstering a pharmacologically-effective amount of one of the foregoing compounds.

Abstract: The invention provides compounds represented by the general formula ##STR1## where R.sub.2, R.sub.3 and R.sub.4 are each selected from the group consisting of H, and OA; A is H or ##STR2## R.sub.5 is selected from the group consisting of alkyl and aromatic residues; n is 2 or 3; and R.sub.1 is selected from the group consisting ##STR3## wherein R.sub.6 is selected from the group consisting of halogen, hydrocarbyl and hetero atom-substituted hydrocarbyl, comprising from 1 to 12 carbon atoms and wherein said hetero-atoms are selected from the group consisting of halogen, nitrogen, oxygen, sulfur and phosphorus; R.sub.7 is R.sub.6 or H and m equals 1, 2 or 3; with the proviso that at least one of R.sub.2, R.sub.3 and R.sub.4 is H, that at least one of R.sub.2, R.sub.3 and R.sub.4 is not H and that R.sub.2 and R.sub.4 are not both OA; and pharmaceutically-acceptable salts thereof. The compounds are dopamine receptor agonists and useful for the treatment of glaucoma in mammals.

Abstract: This invention provides a method for reducing the intraocular pressure in mammals which comprises administering an effective amount of a compound selected from the group consisting of compounds represented by the general formula: ##STR1## where R.sub.2, R.sub.3 and R.sub.4 are each selected from the group consisting of H, and OA; A is H or ##STR2## R.sub.5 is selected from the group consisting of alkyl and aromatic residues; n is 2 or 3; and R.sub.1 is selected from the group consisting of 3-hydroxyphenyl, 4-hydroxyphenyl, 3-pyridyl, 4-pyridyl, ##STR3## where X is S, O or NH, with the proviso that at least one of R.sub.2, R.sub.3 and R.sub.4 is H, that at least one of R.sub.2, R.sub.3 and R.sub.4 is not H and that R.sub.2 and R.sub.4 are not both OA; and pharmaceutically-acceptable salts thereof. This invention further provides compositions useful in such method of reducing the intraocular pressure in mammals.

Abstract: Compounds having calcium channel antagonist activity of the formula: ##STR1## wherein R.sub.1 and R.sub.2 are each independently amino, trifluoromethyl, pentafluoroethyl, alkoxy, lower alkenyl, or lower alkynyl or branched or unbranched lower alkyl, which is unsubstituted or is substituted with cyano, hydroxy, acyloxy, hydrazino, lower alkyl amino, or di(lower alkyl)-amino or 5 or 6 membered saturated nitrogen-containing heterocyclic-1-yl, which is unsubstituted or is substituted with oxo, hydroxy, alkyl, and hydroxy (lower alkyl) R.sub.3 is straight- or branched-chain C.sub.1 to C.sub.12 alkyl, alkenyl, alkynyl, or cycloalkyl, and is either unsubstituted or substituted with hydroxy, acyloxy, cyano, di(lower alkyl) amino 5- or 6-membered saturated nitrogen-containing heterocyclic-1-yl or R.sub.3 is --A-R.sub.4, A is a straight- or branched-chain hydrocarbon moiety containing from 2 to 12 carbon atoms and from 0 to 2 double bonds, R.sub.4 is selected from the group consisting of: ##STR2## R.sub.

Abstract: A flash chromatography apparatus and method for rapid, moderate-resolution separation of organic compounds. A solvent reservoir is pressurized with a gas, forcing solvent under pressure through tubing into and through a sorbent-packed chromatography column. More than one solvent reservoir may be provided to permit mixed-solvent elution. Alternatively, instead of pressurizing the solvent with compressed air, one or more metering pumps may be used to deliver solvent to the column. The method includes introducing a sample to be eluted into the top of a flash chromatography column, beginning elution by introducing an elution solvent under pressure into the top of the column, the elution solvent comprising a first solvent and a second solvent in a ratio from 0:1 to 1:0, modifying the elution solvent by varying the ratio of the first solvent to the second solvent, and continuing elution with the modified elution solvent.

Abstract: A method for sterilizing contact lenses and especially hydrophilic (soft) contact lenses comprising contacting a contact lens for a period of time sufficient to sterilize the lens with a substantially isotonic, aqueous composition having a pH between 6-9 comprising about 0.01 to about 0.3 percent by weight of an ene-diol compound and from about 0.1 to about 25 ppm copper ion. Preferred ene-diol compounds are dihydroxyfumaric acid and dihydroxymaleic acid.

Abstract: A method for sterilizing contact lenses and especially hydrophilic (soft) contact lenses comprising contacting a contact lens for a period of time sufficient to sterilize the lens with a substantially isotonic, aqueous composition having a pH between 6-9 comprising about 0.01 to about 0.3 percent by weight of an ene-diol compound such as reductic acid and from about 0.1 to about 25 ppm copper ion.

Abstract: Novel compounds useful as dopamine receptor agonists for the treatment of various diseases of the central nervous system such as Parkinson's disease and related disorders having the structural formula ##STR1## where R.sub.2, R.sub.3 and R.sub.4 are each selected from the group consisting of H, and OA; A is H or ##STR2## R.sub.5 is selected from the group consisting of alkyl and aromatic residues; n is 2 or 3; and R.sub.1 is selected from the group consisting of 3-hydroxyphenyl, 4-hydroxyphenyl, 3-pyridyl, 4-pyridyl, ##STR3## where X is S, O or NH; and pharmaceutically acceptable salts thereof. Also disclosed is a method for inducing a dopaminergic response in a patient by adminstering a pharmacologically-effective amount of one of the foregoing compounds.

Abstract: In a method for administering systemically active agents including therapeutic agents through the skin or other body membranes of humans and animals typically in the form of a transdermal device or formulation, the improvement comprising the use therewith of an effective amount of a membrane penetration enhancer having the structural formula. ##STR1## wherein R is H or a lower alkyl group, m is 5-7 and n is 0-17.

Abstract: Compounds are disclosed having the formula: ##STR1## wherein: R.sub.1 is H, OH, --OCH.sub.3, --CH.sub.2 OH, --NH.sub.2, --NHMe, --NHEt, --NMe.sub.2, --NEt.sub.2, ##STR2## R.sub.2 is H, --CH.sub.3, or ##STR3## R.sub.3 is phenyl, benzyl, or 1-4 carbon alkyl; R.sub.4 is H, --CH.sub.3, --CH.sub.2 OH, --CH.sub.2 --CN, --CH.sub.2 --S--Me, CH.sub.2 --S--CN, or ##STR4## R.sub.5 is H, 1-4 carbon alkyl, alkenyl, or alkynyl, or aralkyl having a 1-4 carbon alkylene moiety; and A is --CH.sub.2 --or --CH.sub.2 CH.sub.2 --, and pharmaceutically-acceptable salts thereof. Pharmaceutical preparations using these compounds and a method for inducing a dopaminergic response by administering these compounds are also disclosed.

Abstract: The disclosure describes a method for improved plant pest control comprising contacting a plant or plant pest with a composition comprising an effective amount of a plant pesticide and an effective delivery enhancing amount of compound having the structural formula ##STR1## wherein R' is H or a lower alkyl group having 1-4 carbon atoms, m is 3-7, n is 0-17 and R is --CH.sub.3, ##STR2## where R" is H or halogen, with the proviso that if m is 3 and R is CH.sub.3, then n is 5-17.Typical plant pesticides include insecticides, fungicides, herbicides, rodenticides, nematicides molluscicides and acaricides. The preferred penetration enhancing compound is 1-n-dodecylaza cycloheptan-2-one.

Abstract: A method for sterilizing contact lenses and especially hydrophilic (soft) contact lenses comprising contacting a contact lens for a period of time sufficient to sterilize the lens with a substantially isotonic, aqueous composition having a pH between about 6-9 comprising about 0.01 to about 0.3 percent by weight of an ene-diol compound and from about 0.1 to about 25 ppm copper ion. Preferred ene-diol compounds are ascorbic acid and dihydroxymaleic acid.

Abstract: Pharmaceutical compositions containing triethylenetetramine (trien) useful in treating skin disorders. Trien may be used alone to treat inflammation of the skin or may be combined with additional anti-inflammatory, anti-infective or antimitotic agents in the treatment of skin disorders such as acne, psoriasis, seborrhea and dermatitis. Trien also forms a clear solution or gel with zinc pyrithione.

Abstract: Compositions useful for carrying physiologically active agents such as therapeutic agents through skin and other body membranes comprising the agent and an effective, non-toxic amount of a compound having the structural formula ##STR1## wherein R' is H or a lower alkyl group, m is 3-7, N is 0-17 and R is --CH.sub.3, phenyl or substituted phenyl or ##STR2## with the proviso that if m is 3 and R is --CH.sub.3, then n is not 0-6.

Abstract: A method for temporarily reducing pain in animals including humans, and especially pain associated with gastrointestinal dysfunction, by administering to an animal having pain an effective, pain reducing amount of dextromethorphan, preferably as the hydrobromide.

Abstract: Compositions especially useful for treating inflammation topically in animals comprising an active compound having the structural formula ##SPC1##Where R is H, lower alkyl, lower alkoxy, halogen, CF.sub.3, NO.sub.2, OH, CN, COOR.sub.1, ##EQU1## NHCOR.sub.1 or NR.sub.1 R.sub.2 where R.sub.1 and R.sub.2 are each selected from the group consisting of H and lower alkyl, R, R.sub.1 and R.sub.2 being the same or different, and n is 0-5; and where X is an alkyl or alkenyl chain having 2-8 carbon atoms, one of which carbon atoms may be in the form of a carbonyl group, and Y is hydrogen, alkyl, aryl, aralkyl or aryl and aralkyl substituted with one or more R; and pharmaceutically acceptable salts thereof, together with a pharmaceutical carrier containing an effective amount of an active radical having the structural formula ##SPC2##Where n is 1-4 and A is H or ##SPC3##And Z is H or --CH=NOH or --CONHOH and one and only one Z in a heterocyclic ring is H.

Abstract: A method for assaying prostaglandins of the F.sub..alpha. series by reacting a compound of this series with a compound having the formula R--B(OH).sub.2 wherein R is a radical containing a fluorescent or radioactive label, isolating the reaction product and measuring the amount of fluorescence or radioactivity of the reaction product.

Abstract: A method for assaying prostaglandins of the E and F series comprising the sequential steps of reducing the keto groups in a sample containing the prostaglandins to hydroxy groups, selectively oxidizing the prostaglandin 15-OH groups to keto groups, reducing the keto groups to hydroxy groups by means of a radioactive labeled chemical reducing agent, isolating radioactive labeled prostaglandins and measuring the amount of radioactivity of the isolated radioactive labeled prostaglandins.

Abstract: A method for assaying prostaglandins of the E series by reacting a compound of this series with NaB.sup.3 H.sub.4, isolating the tritiated prostaglandin and measuring its radioactivity.

Abstract: There is disclosed a method for topically administering griseofulvin to a human or animal in a manner such that a high degree of epidermal, especially stratum corneum, retention of griseofulvin is attained by contacting the skin of a human or animal with an effective amount of a therapeutic composition containing griseofulvin and 2-pyrrolidone or an N-lower alkyl-2-pyrrolidone.